ChemoCentryx’s Lead Drug Meets Phase II Objective; Novartis
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 12, 2014.ChemoCentryx Inc (NASDAQ: CCXI) gained more than 70 percent Friday on news that its lead drug candidate met with success in a Phase II study. Shares of the company changed hands recently at $7.57, up…